Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism. [Carta]: 2022 updated systematic review and meta-analysis of randomized controlled trials (2022)
- Authors:
- Autor USP: PRATA, PEDRO HENRIQUE DE LIMA - FMRP
- Unidade: FMRP
- DOI: 10.1186/s13045-022-01289-1
- Subjects: ANTICOAGULANTES; TROMBOEMBOLISMO; NEOPLASIAS; ENSAIO CLÍNICO
- Keywords: Cancer; Venous thromboembolism; Direct oral anticoagulant; Low-molecular-weight heparin
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of Hematology & Oncology
- ISSN: 1756-8722
- Volume/Número/Paginação/Ano: v. 15, n. 1, art. 69, 2022
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
FRERE, Corinne et al. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism. [Carta]: 2022 updated systematic review and meta-analysis of randomized controlled trials. Journal of Hematology & Oncology. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1186/s13045-022-01289-1. Acesso em: 13 fev. 2026. , 2022 -
APA
Frere, C., Farge, D., Schrag, D., Prata, P. H. de L., & Connors, J. M. (2022). Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism. [Carta]: 2022 updated systematic review and meta-analysis of randomized controlled trials. Journal of Hematology & Oncology. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1186/s13045-022-01289-1 -
NLM
Frere C, Farge D, Schrag D, Prata PH de L, Connors JM. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism. [Carta]: 2022 updated systematic review and meta-analysis of randomized controlled trials [Internet]. Journal of Hematology & Oncology. 2022 ; 15( 1):[citado 2026 fev. 13 ] Available from: https://doi.org/10.1186/s13045-022-01289-1 -
Vancouver
Frere C, Farge D, Schrag D, Prata PH de L, Connors JM. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism. [Carta]: 2022 updated systematic review and meta-analysis of randomized controlled trials [Internet]. Journal of Hematology & Oncology. 2022 ; 15( 1):[citado 2026 fev. 13 ] Available from: https://doi.org/10.1186/s13045-022-01289-1 - A review of latest clinical practice guidelines for the management of cancer-associated thrombosis
- Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria [Carta]: a multicenter real-life study
- IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria [Carta]
- Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria
- Immunogenetic, molecular and clinical determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria
Informações sobre o DOI: 10.1186/s13045-022-01289-1 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003267676.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
